Notably, because the RRBP1 pathways of activation and inhibition differ among cancer types, precise guidance of treatment and localization of its subcellular mode of action are necessary, in conjunction with spatial transcriptomics technology to potentially achieve precise spatiotemporal targeting in the future. Here, RRBP1 is linked to cancer.